Influence of Partner Characteristics and Relational Capital on the Success of Business/Nonprofit Organization Partnerships

The 2030 Agenda for Sustainable Development is the largest framework of global cooperation for human and environmental development on a global scale. This framework requires new responses in the social and political spheres. To a large extent, these can come from different economic and social sectors working together to create synergies that will allow quantitatively significant progress to be made towards the United Nations’ Sustainable Development Goals (SDGs). Because of that, in the last few decades, the number of cross-sector social partnerships, and, in particular, partnerships between businesses and nonprofit organizations (NPOs), has increased enormously. However, despite their importance, a large proportion of these partnership processes have been unsuccessful due to the different characteristics of the partners and the relational complexity involved in the multiple factors that affect the collaboration over time. In this regard, the business-NPO literature has stressed the importance of improving the existing understanding of the main factors which favour a partnership’s success as well as the interrelationships among those factors. Following different theoretical perspectives used mainly in the context of business-to-business collaborative relationships, the authors test how partner characteristics indirectly influence the success of the partnerships through relational capital. The results, based on a sample (n = 102) of Spanish businesses in collaboration relationships with NPOs, show that partner characteristics (shared values and resource complementarity) help in the formation of relational capital (trust, information sharing, and commitment), and that this positively influences the success of such partnership processes (achievement of objectives and satisfaction of the partners)

Participación educativa

Monográfico con el título: 'La autonomía de los centros educativos'. Resumen basado en el de la publicaciónEn el curso 2006-2007 se inició en el IES Mariano José de Larra un proyecto pedagógico de cuatro años para mejorar la convivencia y los resultados académicos en la ESO. En primero y segundo de la ESO se han trabajado principalmente aspectos básicos de convivencia (asistencia, orden, cumplimiento de normas), y en tercero y cuarto se ha buscado la mejora académica de los alumnos con su adiestramiento en organización del trabajo y técnicas de estudio. Todas estas actuaciones tienen bases comunes. Por un lado, unificar los esfuerzos de todos los implicados, para lo cual es fundamental la comunicación y la coordinación, y por otro, realizar un seguimiento personalizado de cada alumno. El proyecto plasma sus objetivos y métodos en la firma de un compromiso académico por parte de alumno, familia y centro, cuyo cumplimiento controlan tutores y coordinadores de curso.MadridES

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols